Author: Latika Gupta; Durga Misra; Vishwesh Agarwal; Suma Balan; Vikas Agarwal
Title: Management of rheumatic diseases in the times of COVID-19 pandemic- perspectives of rheumatology practitioners from India Document date: 2020_4_7
ID: 2kkw9nwa_6
Snippet: Of the 861 invitees, 221 responded. In the wake of the pandemic, 47.5% would reduce biological DMARDs (bDMARDs) while only 12.2% would reduce the use of conventional synthetic DMARDs. 64.2% were likely to defer change in IS, the reluctance being most with rituximab (58.3%) followed by cyclophosphamide (53.3%), anti-tumor necrosis factor alpha agents (52.4%) and Janus kinase inhibitors (34.39%)......
Document: Of the 861 invitees, 221 responded. In the wake of the pandemic, 47.5% would reduce biological DMARDs (bDMARDs) while only 12.2% would reduce the use of conventional synthetic DMARDs. 64.2% were likely to defer change in IS, the reluctance being most with rituximab (58.3%) followed by cyclophosphamide (53.3%), anti-tumor necrosis factor alpha agents (52.4%) and Janus kinase inhibitors (34.39%).
Search related documents:
Co phrase search for related documents- anti tumor necrosis factor and change defer: 1
- anti tumor necrosis factor and Janus kinase inhibitor: 1
- anti tumor necrosis factor and kinase inhibitor: 1
- anti tumor necrosis factor and necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- anti tumor necrosis factor and pandemic wake: 1
- anti tumor necrosis factor and rituximab reluctance: 1
- biological dmard and conventional synthetic dmard: 1
- biological dmard and necrosis factor: 1
- biological dmard and synthetic dmard: 1, 2, 3
- change defer and necrosis factor: 1
- change defer and pandemic wake: 1
- change defer and rituximab reluctance: 1
- conventional synthetic dmard and necrosis factor: 1
- conventional synthetic dmard and synthetic dmard: 1, 2, 3, 4
- Janus kinase inhibitor and kinase inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- Janus kinase inhibitor and necrosis factor: 1, 2, 3, 4
- kinase inhibitor and necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- necrosis factor and pandemic wake: 1, 2
- necrosis factor and synthetic dmard: 1
Co phrase search for related documents, hyperlinks ordered by date